Antileukaemic Activity of 5-Aza-2-deoxycytidine in Leukaemia Patients
Author Information
Author(s): D.J. Richel, L.P. Colly, J.C. Kluin-Nelemans, R. Willemze
Primary Institution: University Medical Centre, Leiden, The Netherlands
Hypothesis
Does 5-Aza-2-deoxycytidine (Aza-dC) combined with Amsacrine have antileukaemic properties in patients with relapsed and resistant leukaemia?
Conclusion
The combination of Aza-dC and Amsacrine shows significant antileukaemic effects in patients who have not previously received extensive Ara-C therapy.
Supporting Evidence
- Eight out of 11 patients in their first relapse of acute leukaemia achieved complete remission.
- Combination therapy with Aza-dC/Amsacrine induced a considerable period of granulocytopenia lasting 28-35 days.
- Aza-dC caused less nausea and vomiting compared to Ara-C, making it better tolerated.
- Non-haematologic side effects included severe gastrointestinal and neurological complications.
Takeaway
This study tested a new medicine called Aza-dC to help kids with a type of blood cancer. It worked really well for some kids who hadn't tried other medicines before.
Methodology
Patients were treated with Aza-dC alone or in combination with Amsacrine, and their responses were monitored for remission and side effects.
Limitations
The study had a small sample size and did not include patients who had previously undergone extensive Ara-C therapy.
Participant Demographics
The median age of participants was 38.5 years, with a mix of acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) cases.
Want to read the original?
Access the complete publication on the publisher's website